All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

/images/Cortellis_Flagship_Logo_TM_RGB_Color.png
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • Diagnosing and tracking COVID-19
    • Drugs to Watch 2020
    • The next pandemic
    • Premium reports
      • BioWorld Financings Reports
      • Disease Forecast Reports

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, March 7, 2021
Home » Topics » Deals and M&A

Deals and M&A
%{topic} RSS Feed RSS

$180M milestones: Pfizer buys into Imcyse immunotherapy platform in RA deal

Feb. 3, 2021
By Cormac Sheridan
No Comments
DUBLIN – Imcyse SA has successfully parlayed a research collaboration it entered with Pfizer Inc. in 2017 into a license agreement, under which it will finalize preclinical development of a drug candidate for rheumatoid arthritis (RA) based on its Imotope technology in return for an undisclosed up-front payment, equity investment and up to $180 million in milestones, as well as tiered royalties on product sales.
Read More
Cannabidiol

Jazz proves its chops; harmonic rhythm with GW in $7.2B deal

Feb. 3, 2021
By Randy Osborne
No Comments
Questions about the price tag, the extent of diligence done on intellectual property, and the staying power of Epidiolex (cannabidiol) as well as the potential of other prospects in the acquiree’s pipeline bubbled up during the conference call related to Jazz Pharmaceuticals plc’s whopping takeover of GW Pharmaceuticals plc.
Read More
Microscope and coronavirus illustration

Shionogi grants U.S., U.K. and European rights for COVID-19 treatment to Bioage

Feb. 2, 2021
By David Ho and Gina Lee
No Comments
HONG KONG – Osaka, Japan-based Shionogi & Co. Ltd. has inked a license agreement with Bioage Labs Inc. that sets the stage for the Richmond, Calif.-based startup to test asapiprant for the treatment of COVID-19 and age-related declines in immune function.
Read More
Gold wireframe handshake

Coherus surges into immuno-oncology with $1.1B Junshi deal

Feb. 2, 2021
By Lee Landenberger
No Comments
Shanghai Junshi Biosciences Co. Ltd. could receive an aggregate $1.1 billion from Coherus Biosciences Inc. for the rights to develop and commercialize Junshi’s anti-PD-1 antibody toripalimab in the U.S. and Canada. The deal is powered by Coherus’ core biosimilar business and is designed to steer the company into the business of immuno-oncology.
Read More
Packaging and kit components

Ellume signs $231M supply agreement with U.S. government for COVID-19 home tests

Feb. 2, 2021
By Tamra Sami
No Comments
PERTH, Australia –Digital diagnostics company Ellume Ltd. announced a US$231.8 million agreement with the U.S. Department of Defense (DoD), in coordination with the Department of Health and Human Services (HHS), to accelerate domestic U.S. production of its COVID-19 home tests. The agreement includes funding to support the establishment of Ellume’s U.S.-based manufacturing facility and the delivery of 8.5 million COVID-19 home tests that will be distributed across the U.S.
Read More
Acquisition target

Horizon to buy Viela Bio in $3.05B bid to expand rare disease portfolio

Feb. 1, 2021
By Michael Fitzhugh
No Comments
Seeking to accelerate the company's long-term growth through an expansion of its rare disease pipeline, Horizon Therapeutics plc said Feb. 1 it will buy Viela Bio Inc. for $3.05 billion, or $53 per share (NASDAQ:VIE). Once closed, the deal would add a new commercial-stage asset, Uplizna (inebilizumab), to Horizon's portfolio alongside its current lead products, Tepezza (teprotumumab) for the treatment of thyroid eye disease and Krystexxa (pegloticase) for uncontrolled gout. Dublin-based Horizon, which had $2.08 billion in cash at the end of 2020, borrowed $1.3 billion to help finance the transaction. Astrazeneca plc also enabled the deal by agreeing to divest its 26.7% share in Viela Bio for a profit of between $760 million and $780 million.
Read More

Coherus surges into immuno-oncology with $1.1B Junshi deal

Feb. 1, 2021
By Lee Landenberger
No Comments
Shanghai Junshi Biosciences Co. Ltd. could receive an aggregate $1.1 billion from Coherus Biosciences Inc. for the rights to develop and commercialize Junshi’s anti-PD-1 antibody toripalimab in the U.S. and Canada. The deal is powered by Coherus’ core biosimilar business and is designed to steer the company into the business of immuno-oncology.
Read More

Neubase acquires gene modulation tech from Vera Therapeutics

Jan. 28, 2021
By Michael Fitzhugh
No Comments
In a move that will enable both a broadening of its portfolio and a strengthening of its IP position, Neubase Therapeutics Inc. has acquired technology from Vera Therapeutics Inc. for creating peptide-nucleic acid scaffolds. The deal will extend the ability of Neubase's Patrol platform, a tool for addressing the causal mechanism of genetic disease, to directly modulate the human genome to resolve both rare and common diseases, including cancers, the company said.
Read More
Return arrow

Hairy situation? Innate’s Lumoxiti give-back rattling to some

Jan. 28, 2021
By Randy Osborne
No Comments
Innate Pharma SA’s unexpected return to partner Astrazeneca plc all rights, in the U.S. and EU, to Lumoxiti (moxetumomab pasudotox-tdfk) for hairy cell leukemia likely triggered unease in at least some investors.
Read More

Shionogi grants U.S., U.K. and European rights for COVID-19 treatment to Bioage

Jan. 28, 2021
By David Ho and Gina Lee
No Comments
HONG KONG – Osaka, Japan-based Shionogi & Co. Ltd. has inked a license agreement with Bioage Labs Inc. that sets the stage for the Richmond, Calif.-based startup to test asapiprant, originally developed for allergic rhinitis, for the treatment of COVID-19 and age-related declines in immune function.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 69 70 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for March 5.
  • Gloved hand places sample tubes in PCR system

    COVID-19 test makers are adapting for variants

    BioWorld MedTech
    As COVID-19 variants have emerged, so have questions about the effectiveness of tests for infection. While the risk of mutations significantly limiting their...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for March 5.
  • Coronavirus vaccine/therapeutics illustration

    Tonix looks to the past for the future of COVID-19 vaccines and testing

    BioWorld MedTech
    Tonix Pharmaceuticals Holding Corp. is looking to lessons from tuberculosis and smallpox to guide its future in infectious diseases. The company is developing an...
cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • About
    • Archives
    • Today's news
    • Search BioWorld Science
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
A Clarivate Analytic solution. Link to Clarivate website.
Follow Us

Copyright ©2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing